A Prokinetic Agent with a Dual Effect – Itopride – In the Treatment of Dysmotility

*Petr Dite, Martin Rydlo, Milan Dockal, Arnost Martinek

Academic Centre of Gastroenterology, Department of Internal Medicine of the University Hospital and the Faculty of Medicine of the University of Ostrava, Ostrava, Czech Republic
*Correspondence to pdite.epc@gmail.com

Disclosure: Authors declare that they have nothing to disclose.
Received: 12.09.14 Accepted: 17.10.14
Citation: EMJ Gastroenterol. 2014;3:42-47.


A wide range of dyspeptic symptoms in clinical practice reflect the high prevalence of functional disorders of the gastrointestinal (GI) tract. Prokinetic agents are the current mainstay in the therapy of functional dyspepsia. One of these drugs is itopride. We evaluated therapeutic efficacy of itopride according to the literature review. The therapeutic potential of itopride is connected with a dual effect: influencing of enzyme acetylcholinesterase activity and blocking dopamine D2 receptors. After the itopride administration, the contractility of smooth muscle in the upper GI tract increases. Itopride is a drug with rapid absorption from the small bowel; its peak serum concentration occurs 35 minutes after oral administration. Itopride does not pass the blood-brain barrier and does not affect the heart rate by influencing the QT segment. Itopride is a safe prokinetic agent with positive influence on the symptoms of functional dyspepsia such as postprandial fullness, bloating, and gastric emptying. Itopride could also be used for the therapy of the mild form of gastro-oesophageal reflux.

Download (PDF, 79KB)

Comments are closed.